BAJAJ BROKING
Torrent Investments to divest up to 2.9% stake in Torrent Pharma through block deals. The floor price set at ₹3,022.71 per share, with a deal value possibly reaching ₹3,000 crore.
Torrent Investments, a primary promoter of Torrent Pharmaceuticals, is set to sell up to 2.9% of its stake in the company via block deals. The sale floor price has been set at ₹3,022.71 per share, aiming to raise as much as ₹3,000 crore. This transaction will reduce Torrent Investments’ ownership in Torrent Pharma from its current 71.25% stake, as reported for the September quarter.
The block deal involves a base size of 2.4% of Torrent Pharma’s total equity, with an additional upsize option of 0.5%, bringing the potential sale up to 2.9%. The sale price of ₹3,022.71 per share represents the minimum price at which the transaction is likely to be executed. This floor price is designed to provide a pricing benchmark for prospective buyers, ensuring a structured valuation of Torrent Pharma shares throughout the transaction.
Torrent Investments has also agreed to a lock-up period of 120 days, during which it will refrain from selling additional shares. This lock-up term aims to stabilise the market following the sale, limiting further share dilution and providing assurance to investors regarding the promoter’s continued commitment.
The divestment could raise Torrent Investments an estimated ₹3,000 crore, depending on market reception and share uptake. For Torrent Pharma, the stake reduction may introduce more liquidity into its shares, potentially making the company’s stock more accessible to institutional and retail investors. However, this reduction in promoter holding may affect market perception, especially as the company navigates a competitive pharmaceutical landscape.
With Torrent Pharma’s share price currently trading near the floor price, the block deal is likely to create activity within the stock’s trading volumes. The sale by Torrent Investments could influence Torrent Pharma share price, as increased liquidity typically allows for more trading flexibility among investors. However, with a 120-day lock-up in place, investors may view this as a signal of the promoter’s intent to maintain a long-term interest in Torrent Pharma’s growth and stability.
In the long term, this block deal can serve as a strategic opportunity for Torrent Pharma to broaden its shareholder base and improve its market liquidity, potentially bolstering its position in the pharmaceutical sector.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading